What does the research say about IGSF3?

IGSF3

There are 3 papers on IGSF3 in aging research: 2 observational studies in people.

3 papers study it2 findings

The findings reach people, from one lab or study. 1 lab in 1 country.

“Mediation analyses demonstrated that IGSF3 mediated 19.5% of the PRISm-T2D association, 12.8% for FCMD, and 11.3% for CMM”

Type 2 diabetes

mediatesin humans1

1 study

IGSF3 is linked with type 2 diabetes in humans (PRISm-T2D association) (19.5%).
“Mediation analyses demonstrated that IGSF3 mediated 19.5% of the PRISm-T2D association, 12.8% for FCMD, and 11.3% for CMM”
HumansPRISm-T2D associationplasma14.37 yearsn = 32,689
Plasma proteomic signatures linking preserved ratio impaired spirometry to cardiometabolic diseases and multimorbidity: A longitudinal cohort study
PulmonologyApr 7, 2026

Chronic liver disease progression

upin silico1

1 study

IGSF3 is associated with chronic liver disease progression in silico.
“IGSF3, FTCD, DCXR, ADH1B and ACY1 were associated with CLD progression.”
In silico
Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases
Diabetes, obesity & metabolismMar 26, 2026